CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Press releases

January 17, 2023

The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

Cambridge, UK, 17th January 2023: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ

Category iconPress releases

paul-brooks

December 19, 2022

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

Key strategic appointment as the Company enters next phase of commercial growth and global expansion of its products and services. Former CEO, Dr

Category iconPress releases

July 19, 2022

CN Bio opens new laboratory facilities to extend Organ-on-a-chip contract research services capabilities

State-of-the-art laboratories significantly expand project capacity to meet increasing market demand for Organ-on-a-Chip research services Cambridge,

Category iconPress releases

May 24, 2022

CN Bio appoints Dr Paul Brooks as Chief Business Officer

Cambridge, UK, 24 May 2022: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ

Category iconPress releases

April 26, 2022

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and

Category iconPress releases

December 1, 2021

PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021′

Next generation Organ-on-a-Chip technology listed second in Top 10 Innovations for 2021 System enables pre-clinical studies that simulate complex

Category iconPress releases

November 9, 2021

CN Bio and iiCON announce COVID-19 research collaboration

Partnership focused on validation of novel Organ-on-a-Chip infection models Human-relevant single and multi-organ SARS-CoV-2 infected models

Category iconPress releases

October 5, 2021

CN Bio expands service offering to support oncology drug discovery

New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix™ PK system

Category iconPress releases

July 27, 2021

CN Bio licenses human gut organ microbiome modelling tool from MIT and Northeastern University

Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect

Category iconPress releases

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023